Moors & Cabot Inc. Sells 7,800 Shares of Teva Pharmaceutical Industries Ltd (TEVA)

Moors & Cabot Inc. reduced its holdings in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 28.2% in the 1st quarter, HoldingsChannel reports. The fund owned 19,900 shares of the company’s stock after selling 7,800 shares during the period. Moors & Cabot Inc.’s holdings in Teva Pharmaceutical Industries were worth $316,000 at the end of the most recent reporting period.

A number of other large investors have also bought and sold shares of TEVA. FMR LLC grew its holdings in shares of Teva Pharmaceutical Industries by 44.0% during the fourth quarter. FMR LLC now owns 35,248,665 shares of the company’s stock worth $543,534,000 after buying an additional 10,766,729 shares in the last quarter. Brahman Capital Corp. grew its holdings in shares of Teva Pharmaceutical Industries by 67.3% during the fourth quarter. Brahman Capital Corp. now owns 12,248,106 shares of the company’s stock worth $188,866,000 after buying an additional 4,925,245 shares in the last quarter. Polaris Capital Management LLC grew its holdings in shares of Teva Pharmaceutical Industries by 4.4% during the fourth quarter. Polaris Capital Management LLC now owns 10,342,980 shares of the company’s stock worth $159,489,000 after buying an additional 431,942 shares in the last quarter. Norges Bank purchased a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter worth about $146,130,000. Finally, Northern Trust Corp grew its holdings in shares of Teva Pharmaceutical Industries by 2.7% during the fourth quarter. Northern Trust Corp now owns 6,687,764 shares of the company’s stock worth $103,125,000 after buying an additional 175,173 shares in the last quarter. Hedge funds and other institutional investors own 67.00% of the company’s stock.

A number of equities research analysts have recently commented on the stock. Wells Fargo & Co reiterated a “hold” rating on shares of Teva Pharmaceutical Industries in a report on Friday, May 10th. Royal Bank of Canada set a $19.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a report on Friday, May 3rd. BMO Capital Markets set a $17.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a report on Friday, May 3rd. Morgan Stanley set a $16.00 price target on shares of Teva Pharmaceutical Industries and gave the stock a “hold” rating in a report on Friday, May 3rd. Finally, Cantor Fitzgerald lifted their price target on shares of Teva Pharmaceutical Industries from $16.00 to $25.00 and gave the stock a “neutral” rating in a report on Friday, May 3rd. Three investment analysts have rated the stock with a sell rating, sixteen have given a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. The stock has an average rating of “Hold” and an average target price of $20.53.

Teva Pharmaceutical Industries stock opened at $11.86 on Wednesday. Teva Pharmaceutical Industries Ltd has a 1 year low of $11.26 and a 1 year high of $25.96. The company has a market capitalization of $11.70 billion, a P/E ratio of 4.24, a P/E/G ratio of 1.46 and a beta of 1.30. The company has a quick ratio of 0.62, a current ratio of 0.96 and a debt-to-equity ratio of 1.66.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Thursday, May 2nd. The company reported $0.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.55 by $0.02. Teva Pharmaceutical Industries had a negative net margin of 18.66% and a positive return on equity of 16.84%. The firm had revenue of $4.30 billion during the quarter, compared to the consensus estimate of $4.38 billion. During the same period in the previous year, the firm earned $0.94 earnings per share. Teva Pharmaceutical Industries’s revenue was down 15.2% compared to the same quarter last year. On average, research analysts predict that Teva Pharmaceutical Industries Ltd will post 2.26 earnings per share for the current year.

In other Teva Pharmaceutical Industries news, insider Deborah A. Griffin sold 4,107 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Monday, March 4th. The shares were sold at an average price of $16.88, for a total transaction of $69,326.16. Following the transaction, the insider now directly owns 2,941 shares of the company’s stock, valued at $49,644.08. The sale was disclosed in a filing with the SEC, which is available at this link. Also, VP Notaristefani Carlo De sold 16,070 shares of Teva Pharmaceutical Industries stock in a transaction that occurred on Monday, May 20th. The shares were sold at an average price of $11.42, for a total transaction of $183,519.40. Following the transaction, the vice president now directly owns 49,659 shares in the company, valued at $567,105.78. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 28,349 shares of company stock valued at $384,241. 0.49% of the stock is owned by insiders.

TRADEMARK VIOLATION WARNING: “Moors & Cabot Inc. Sells 7,800 Shares of Teva Pharmaceutical Industries Ltd (TEVA)” was reported by Markets Daily and is the property of of Markets Daily. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at https://www.themarketsdaily.com/2019/05/22/moors-cabot-inc-sells-7800-shares-of-teva-pharmaceutical-industries-ltd-teva.html.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.

Recommended Story: What is a stock buyback?

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).

Institutional Ownership by Quarter for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.